Page last updated: 2024-12-06

xanthosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Xanthosine is a purine nucleoside composed of xanthine and ribose. It is a naturally occurring compound found in various tissues and fluids, including urine. Xanthosine is formed as a byproduct of purine metabolism and can be synthesized chemically through the reaction of xanthine with ribose. Its biological effects include acting as a vasodilator, potentially modulating the immune system, and showing antioxidant properties. The research interest in xanthosine stems from its potential therapeutic applications, such as treating cardiovascular diseases, inflammatory conditions, and neurodegenerative disorders. Its antioxidant potential makes it a subject of study in aging and age-related diseases.'

Cross-References

ID SourceID
PubMed CID64959
CHEMBL ID402439
CHEBI ID18107
SCHEMBL ID133792
MeSH IDM0047747

Synonyms (54)

Synonym
9-beta-d-ribofuranosylxanthine
9-beta-d-ribofuranosyl-3,9-dihydro-1h-purine-2,6-dione
CHEBI:18107 ,
xanthine 9-beta-d-ribofuranoside
nsc-18930
xanthine riboside
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-2,6-dione
146-80-5
xanthosine ,
C01762
9 beta-d-ribofuranosylxanthine
xanthosine, 9-beta-d-
185DA837-1A29-446F-A96C-EBBA1B464566
CHEMBL402439
beta-d-ribofuranoside, xanthine-9
1h-purine-2,6-dione, 3,9-dihydro-9-beta-d-ribofuranosyl-
ai3-52693
BMSE000128
X0008
9-[(4s,2r,3r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropurine -2,6-dione
S9369
nsc 18930
bm66ht53c3 ,
unii-bm66ht53c3
einecs 205-679-9
SCHEMBL133792
xanthosine [mi]
9-.beta.-d-ribofuranosyl xanthine
1h-purine-2,6-dione, 3,9-dihydro-9-.beta.-d-ribofuranosyl-
AKOS024282554
4uo ,
2,3-dihydroxanthosine
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purine-2,6-diol
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,3,6,9-tetrahydro-1h-purine-2,6-dione
GS-3230
xanthosin
3,9-dihydro-9-b-d-ribofuranosyl-1h-purine-2,6-dione
3,9-dihydro-9-d-ribofuranosyl-1h-purine-2,6-dione
9-beta-delta-ribofuranosylxanthine
3,9-dihydro-9-delta-ribofuranosyl-1h-purine-2,6-dione
3,9-dihydro-9-beta-delta-ribofuranosyl-1h-purine-2,6-dione
9-b-d-ribofuranosylxanthine
9-delta-ribofuranosylxanthine
9-d-ribofuranosylxanthine
HY-W011527
CS-W012243
2,3-dihydro-2-oxoinosine
Q408788
9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purine-2,6-diol
DTXSID90861829
9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purine-2,6(3h,9h)-dione
CCG-267285
9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-2,6-diol
A848549

Research Excerpts

Effects

ExcerptReferenceRelevance
"Xanthosine treatment has been demonstrated to promote expansion of putative mammary stem cells in vivo, and hepatic and hair follicle stem cells in vitro."( In vitro expansion of the mammary stem/progenitor cell population by xanthosine treatment.
Capuco, AV; Choudhary, RK, 2012
)
1.33

Treatment

Xanthosine treatment has been demonstrated to promote expansion of putative mammary stem cells in vivo, and hepatic and hair follicle stem Cells in vitro. XAnthosine also increased the proliferation rate of bovine MEC.

ExcerptReferenceRelevance
"Xanthosine treatment was previously shown to promote expansion of hepatic stem cells in vitro."( In vivo expansion of the mammary stem/ progenitor cell population by xanthosine infusion.
Capuco, AV; Evock-Clover, CM; Minuti, A; Wood, DL, 2009
)
1.31
"Xanthosine treatment has been demonstrated to promote expansion of putative mammary stem cells in vivo, and hepatic and hair follicle stem cells in vitro."( In vitro expansion of the mammary stem/progenitor cell population by xanthosine treatment.
Capuco, AV; Choudhary, RK, 2012
)
1.33
"Xanthosine treatment increased the proliferation rate of bovine MEC in vitro. "( In vitro expansion of the mammary stem/progenitor cell population by xanthosine treatment.
Capuco, AV; Choudhary, RK, 2012
)
2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
xanthosinesAny purine ribonucleoside that is a derivative of xanthosine.
purines D-ribonucleosideA purine ribonucleoside that is a purine derivative attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (42)

PathwayProteinsCompounds
Purine Metabolism3766
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Purine Ribonucleosides Degradation717
Mitochondrial DNA Depletion Syndrome3566
xanthine and xanthosine salvage07
caffeine biosynthesis II (via paraxanthine)011
inosine 5'-phosphate degradation013
adenosine nucleotides degradation I327
theobromine biosynthesis I09
caffeine biosynthesis I011
superpathway of purines degradation in plants745
ureide biosynthesis220
superpathway of guanosine nucleotides degradation (plants)227
guanosine nucleotides degradation I226
purine nucleotides degradation I (plants)334
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Xanthosine + Orthophosphate = Xanthine + D-Ribose 1-phosphate ( Purine nucleotides and Nucleosides metabolism )13
Purine metabolism1336
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
purine ribonucleosides degradation to ribose-1-phosphate316
urate biosynthesis/inosine 5'-phosphate degradation612
purine nucleotides degradation1129
caffeine biosynthesis I012
caffeine biosynthesis II (via paraxanthine)012
adenosine nucleotides degradation I227
purine nucleotides degradation I (plants)234
purine ribonucleosides degradation822
purine nucleotides degradation II (aerobic)2246
inosine 5'-phosphate degradation1324
xanthine and xanthosine salvage312
superpathway of purines degradation in plants645
salvage pathways of guanine, xanthine, and their nucleosides017
Ureide biosynthesis017
Biochemical pathways: part I0466
Purine metabolism and related disorders2353
ureide biogenesis417

Bioassays (7)

Assay IDTitleYearJournalArticle
AID70684Inhibition of Cellular Replication of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID70686Optimum concentration for differentiation of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID329451Inhibition of inosine and alanine-induced germination of Bacillus anthracis Sterne spore pre-incubated for 15 mins2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of an in vivo inhibitor of Bacillus anthracis spore germination.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID329453Inhibition of cytopathic effect in Bacillus anthracis Sterne infected mouse RAW264.7 macrophage after 6 hrs by propidium iodide exclusion assay2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of an in vivo inhibitor of Bacillus anthracis spore germination.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (27.38)18.7374
1990's9 (10.71)18.2507
2000's25 (29.76)29.6817
2010's20 (23.81)24.3611
2020's7 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.01 (24.57)
Research Supply Index4.48 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index56.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.30%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other85 (97.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]